The squamous cell carcinoma of the head and neck treatment market growth is anticipated to be boosted by the rising incidence of head and neck cancer. The head and neck region accounts for about 4% of all cancer cases in the United States, according to the American Society of Clinical Oncology (ASCO). Since more patients are turning to oral therapeutics for their head and neck cancer treatments, it has become clear that the oral route of administration will experience the fastest growth during the forecast period.
According to Data Bridge Market Research, Squamous Cell Carcinoma of the Head and Neck Treatment Market was USD 12 billion in 2022, would rise to USD 24.80 billion by 2030, and is expected to undergo a CAGR of 9.50% during the forecast period 2023 to 2030.
“Increasing healthcare expenditure surge market demand"
The increasing healthcare expenditure globally, especially in developing economies, plays a crucial role in driving the growth of the squamous cell carcinoma of the head and neck treatment market. Higher healthcare spending leads to improved access to healthcare services, including early diagnosis and effective treatment options. This increased accessibility enables patients to receive timely and appropriate care, ultimately driving market growth. Moreover, healthcare expenditure supports the development and adoption of advanced technologies and therapies, further contributing to the expansion of the treatment market.
What restraints the growth of squamous cell carcinoma of the head and neck treatment market?
“High cost can impede the market growth”
The high cost of treatments for squamous cell carcinoma of the head and neck poses a significant restraint on market growth. Newer targeted therapies and immunotherapies, while offering promising outcomes, often come with a hefty price tag. This cost burden can limit patient access to these treatments, particularly in regions with limited healthcare resources or inadequate insurance coverage. Affordability barriers hinder market expansion and highlight the need for cost-effective alternatives and measures to improve the accessibility and affordability of treatment options.
Segmentation: Global Squamous Cell Carcinoma of the Head and Neck Treatment Market
The squamous cell carcinoma of the head and neck treatment market is segmented on the basis of type drug class, type, diagnosis, treatment, therapeutic class, distribution channel and end user.
- On the basis of drug class, the squamous cell carcinoma of the head and neck treatment market is segmented into immunotherapy, chemotherapy, and targeted therapy.
- On the basis of type, the squamous cell carcinoma of the head and neck treatment market is segmented into salivary gland, oral and oropharyngeal, nasal cavity, and paranasal sinuses, nasopharyngeal, laryngeal, and hypopharyngeal.
- On the basis of diagnosis, the squamous cell carcinoma of the head and neck treatment market is segmented into bioscopy screening tests, blood tests, dental diagnosis, imaging, and endoscopy.
- On the basis of treatment, the squamous cell carcinoma of the head and neck treatment market is segmented into radiation, surgery, chemotherapy, and immunotherapy.
- On the basis of therapeutic class, the squamous cell carcinoma of the head and neck treatment market is segmented into pd inhibitors, egfr inhibitors, microtubule inhibitors, mitotic inhibitors.
- On the basis of distribution channel, the squamous cell carcinoma of the head and neck treatment market is segmented into online, and offline.
- On the basis of end user, the squamous cell carcinoma of the head and neck treatment market is segmented into hospitals, specialty clinics, and ambulatory surgical centers.
Regional Insights: Asia-Pacific dominates the Global Squamous Cell Carcinoma of the Head and Neck Treatment Market
Asia-Pacific is expected to grow during the forecast period the squamous cell carcinoma of the head and neck treatment market because of a rising population, a changing way of life, and the adoption of cutting-edge technology. In the coming years, market growth is anticipated to be boosted by an aging population and an increase in the prescription of immunotherapy drugs like Pembrolizumab (Keytruda) and Nivolumab (Opdivo) used to treat a variety of types of HNC.
North America dominates the market in the forecast period because of the region's increasing levels of investment in the creation of cutting-edge technologies like platinum-based therapy. Additionally, government funding for the expansion of the healthcare industry is promoting market expansion.
To know more about the study, visit, https://www.databridgemarketresearch.com/jp/reports/global-squamous-cell-carcinoma-of-the-head-and-neck-treatment-market
Recent Developments in Global Squamous Cell Carcinoma of the Head and Neck Treatment Market
- In 2021, the U.S. FDA granted the breakthrough therapy designation for Tipifarnib, developed by Kura Oncology, Inc., for treating patients suffering from head and neck squamous cell carcinoma (HNSCC). This is a selective, potent, and orally administered drug.
The prominent key players operating in the Global Squamous Cell Carcinoma of the Head and Neck Treatment Market Include:
- Sanofi (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Boehringer Ingelheim International GmbH. (Germany)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd (Israel)
- AbbVie Inc (U.S.)
- Astellas Pharma Inc. (Japan)
- Sumitomo Pharma Co., Ltd (Japan)
- Amgen Inc (U.S.)
- Curis, Inc (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of global squamous cell carcinoma of the head and neck treatment market companies contact, https://www.databridgemarketresearch.com/jp/contact
Research Methodology: Global Squamous Cell Carcinoma of the Head and Neck Treatment Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by dbmr research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, global vs regional and vendor share analysis. Please request analyst call in case of further inquiry.
